Table 5.
Eculizumab treatment trials and resulting outcomes.
| Eculizumab Treatment | |||||
|---|---|---|---|---|---|
| Legendre et al. | Licht et al. | Cofiell et al. | Greenbaum et al. | ||
| Year | 2013 | 2014 | 2014 | 2015 | |
| Sample Size | 37 | 37 | 41 | 22 | |
| Age (Years) | ≥12 | ≥18 + 1 adolescent | ≥18 | 0.4–17 | |
| Primary Endpoints | Platelet normalization (≥150 × 109/L) LDH normalization (<upper limit of normal) eGFR via SCr improved (≥25% reduction from baseline) |
||||
| Secondary Endpoints | 26 weeks = 80% | 26 weeks = 82% | - | 27 weeks = 95% | TMA free outcomes |
| 26 weeks = 100% | 26 weeks = 76% | - | 55 days (median) = 82% | Hematologic normalization | |
| 26 weeks = 100% | - | 6 weeks = sig. ↓ | - | Complement pathway inhibition | |
| 26 weeks = 100% | 26 weeks = 80% | 6 weeks = sig. ↓ | 48 days (median) = 73% | Renal function measure normalization | |
Early Eculizimab trials and resulting outcomes. LDH: lactate dehydrogenase; SCr: serum creatinine; L: liter; eGFR: estimated glomerular filtration rate; TMA: thrombotic angiopathy anemia.